Publication
Article
Author(s):
Levonorgestrel (LNG) 90 μg/ethinylestradiol (EE) 20 μg was shown to havea good endometrial safety profile aftera substudy of a phase 3, open-label, 1-year trial that was conducted at 92sites in the United States and Canada.Healthy, sexually active women, aged18 to 49 years, took 1 pill of LNG 90μg/EE 20 μg daily for 12 months. The 93participants in the histology portion ofthe study had an endometrial biopsy atthe pretreatment visit and during thelast month. The results of the biopsiesshowed no inconsistent changes in theendometria, and there were no findingsof hyperplasia or malignancy.
Ms. Farley is a freelance medicalwriter based in Wakefield, RI.